Histamine regulation of biliary proliferation

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 46, Issue 3, Pages (March 2007)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
Angiogenesis and hepatocellular carcinoma
Volume 59, Issue 5, Pages (November 2013)
Novel insights in the interplay between inflammation and metabolic diseases: A role for the pathogen sensing kinase PKR  Nicolas Marsollier, Pascal Ferré,
Volume 128, Issue 1, Pages (January 2005)
Anatoliy I. Masyuk, Tatyana V. Masyuk, Nicholas F. LaRusso 
Volume 44, Issue 3, Pages (March 2006)
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 52, Issue 3, Pages (March 2010)
Thoetchai (Bee) Peeraphatdit, Douglas A. Simonetto, Vijay H. Shah 
Hedgehog signaling in the liver
The function of serotonin within the liver
Urokinase-induced smooth muscle cell responses require distinct signaling pathways: A role for the epidermal growth factor receptor  Suzanne M. Nicholl,
Immigration and viral hepatitis
Daniel A. Langer, Vijay H. Shah  Journal of Hepatology 
The evidence supports a viral aetiology for primary biliary cirrhosis
Volume 132, Issue 1, Pages (January 2007)
Living donor liver transplantation: is the hype over?
Senescence: Not Just for Tumor Suppression
Mesenchymal stromal cell therapy for liver diseases
Volume 66, Issue 2, Pages (February 2017)
The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury  Veronika Lukacs-Kornek, Frank Lammert 
Histamine in the immune regulation of allergic inflammation
Hepatitis C core protein – The “core” of immune deception?
Volume 59, Issue 5, Pages (November 2013)
Signalling pathways in alcohol-induced liver inflammation
Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance  Kostyantyn Krysan, PhD,
Exosomes in liver pathology
Targeting gut flora to prevent progression of hepatocellular carcinoma
Angiogenesis and hepatocellular carcinoma
Inhibition of mammalian target of rapamycin: Two goals with one shot?
Volume 45, Issue 4, Pages (October 2006)
Autophagy and senescence in fibrosing cholangiopathies
Volume 62, Issue 3, Pages (March 2015)
Volume 130, Issue 6, Pages (May 2006)
EASL Clinical Practice Guidelines: Wilson’s disease
Mona Malz, Federico Pinna, Peter Schirmacher, Kai Breuhahn 
Gregory B. Vanden Heuvel  Kidney International 
Marcel Klingenberg, Akiko Matsuda, Sven Diederichs, Tushar Patel 
Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…
Volume 59, Issue 2, Pages (August 2013)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Salvatore Papa, Concetta Bubici  Journal of Hepatology 
Chetana Lim, Chady Salloum, Daniel Azoulay
Immigration and viral hepatitis
Volume 44, Issue 5, Pages (May 2006)
Macrophage heterogeneity in liver injury and fibrosis
Epigenetic modifications as new targets for liver disease therapies
Volume 65, Issue 4, Pages (October 2016)
Statins: Old drugs as new therapy for liver diseases?
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Volume 60, Issue 6, Pages (June 2014)
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
The balance between Notch/Wnt signaling regulates progenitor cells’ commitment during liver repair: Mystery solved?  Mario Strazzabosco, Luca Fabris 
The origin of biliary strictures after liver transplantation: Is it the amount of epithelial injury or insufficient regeneration that counts?  Negin Karimian,
Volume 54, Issue 6, Pages (June 2011)
EpCAM in hepatocytes and their progenitors
Regulation of cholangiocyte bile secretion
Foxa1 and Foxa2 regulate bile duct development in mice
Genetics of hepatocellular carcinoma: The next generation
Platelets arrive at the scene of fibrosis……studies
Niya Aleksieva, Stuart J. Forbes  Journal of Hepatology 
Volume 60, Issue 6, Pages (June 2014)
Presentation transcript:

Histamine regulation of biliary proliferation Heather Francis, Fanyin Meng, Eugenio Gaudio, Gianfranco Alpini  Journal of Hepatology  Volume 56, Issue 5, Pages 1204-1206 (May 2012) DOI: 10.1016/j.jhep.2011.09.023 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Top panel: In normal and during cholestatic injury, histamine receptors are found in small and large cholangiocyte populations. Expression levels of HRs have not been found to have a significant impact on cholangiocyte response, however, activation of specific histamine receptors results in differential downstream signaling. H1HR couples mainly to Gαq that mobilizes the IP3/Ca2+/PKC-dependent pathway with subsequent increased cholangiocyte proliferation. Our data suggests that the effects of H1HR are predominantly found in small cholangiocytes, as this population is known to signal via Ca2+-dependent pathways. H2HR activates cAMP-dependent mechanisms that increase cholangiocyte proliferation. Large cholangiocyte proliferation is regulated primarily by cAMP activation and our data has supported this concept. The H3 and H4HRs are predominantly inhibitory receptors that are able to either inhibit cAMP synthesis or activate Ca2+/PLC-dependent pathways. The result of H3 or H4 activation is decreased cholangiocyte proliferation that we believe occurs mostly in large cholangiocytes. Bottom panel: During cholangiocarcinoma, histamine and the enzyme responsible for histamine synthesis, histidine decarboxylase (HDC), are upregulated thus activating specific histamine receptors. We have found that after activation of the inhibitory receptors, H3 and H4, cholangiocarcinoma growth decreases. H3HR activates Ca2+/PKCα-dependent signaling that decreases cholangiocarcinoma growth, whereas H4HR signals via Ca2+-dependent mechanisms to decrease EMT, ECM degradation and tumor spreading. We suggest that inhibition of the stimulatory H1 or H2 HR will result in decreased cholangiocarcinoma growth presumably by inhibition of Ca2+-dependent or cAMP-dependent pathways. ECM, extracellular matrix; EMT, epithelial mesenchymal transition; HA, histamine; HDC, histidine decarboxylase; HR, histamine receptors; MMPs, matrix metalloproteins. Journal of Hepatology 2012 56, 1204-1206DOI: (10.1016/j.jhep.2011.09.023) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions